ScholarIQanswers from OpenAlex & ORCID
Roisin E. O’Cearbhaill
ResearcherPublications, citations & collaboration network
Roisin E. O’Cearbhaill is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Roisin E. O’Cearbhaill have?
ScholarIQindexed works
Roisin E. O’Cearbhaill has 412 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Roisin E. O’Cearbhaill have?
ScholarIQcitation count
Roisin E. O’Cearbhaill has 8,761 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Roisin E. O’Cearbhaill?
ScholarIQh-index
Roisin E. O’Cearbhaill has an h-index of 39 in OpenAlex.
What is the i10-index of Roisin E. O’Cearbhaill?
ScholarIQi10-index
Roisin E. O’Cearbhaill has an i10-index of 111 in OpenAlex.
What is the ORCID of Roisin E. O’Cearbhaill?
ScholarIQorcid
The ORCID for Roisin E. O’Cearbhaill is on the source record.
What is the OpenAlex record for Roisin E. O’Cearbhaill?
ScholarIQopenalex
The OpenAlex for Roisin E. O’Cearbhaill is on the source record.
What are the most-cited papers on Roisin E. O’Cearbhaill?
ScholarIQmost cited works
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière, Stephen B. Solomon, Valerie W. Rusch, Roisin E. O’Cearbhaill, Amy Zhu, Waseem Cheema, Navin K. Chintala, Elizabeth Halton, John Pineda, Rocío Pérez-Johnston, Kay See Tan, Bobby Daly, Jose A. Araujo Filho, Daniel Ngai, Erin McGee, A. Vincent, Claudia Diamonte, Jennifer L. Sauter, Shanu Modi, Devanjan Sikder, Brigitte Sénéchal, Xiuyan Wang, William D. Travis, Mithat Gönen, Charles M. Rudin, Renier J. Brentjens, David R. Jones, Michel Sadelain
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru, Roisin E. O’Cearbhaill, Swati Pendharkar, David R. Spriggs, Renier J. Brentjens
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen A. Cadoo, Geoffrey I. Shapiro, Erica L. Mayer, Roisin E. O’Cearbhaill, Robert L. Coleman, Bose Kochupurakkal, Christin Whalen, Jennifer Curtis, Sarah Farooq, Weixiu Luo, Julia Eismann, Mary K. Buss, Carol Aghajanian, Gordon B. Mills, Sangeetha Palakurthi, Paul T. Kirschmeier, Joyce F. Liu, Lewis C. Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D’Andrea, Eric P. Winer, Gerburg M. Wulf, Ursula A. Matulonis